Lonza Group stock holds focus on earnings and margin trends

Lonza Group stock centers on its latest reported revenue, margin, and cash flow metrics as investors track the Swiss healthcare supplier’s operating profile and market value.

Lonza Group (CH0013841017) remains a data-driven story for investors because its latest published revenue, margin, and cash flow figures still frame the stock. The company’s shares cannot be tied to a fresh news item here, but the most recent verified reporting context and market-structure facts still provide a usable view of Lonza Group stock.

Revenue and margin base

Lonza Group reported revenue of CHF 6.71 billion for fiscal 2024, which gives a concrete size reference for the business entering 2026. The same reporting cycle showed a core EBITDA margin of 30.8%, a level that matters because it indicates how much of the top line Lonza keeps after operating costs.

Those figures are useful because they connect scale with profitability in one snapshot. For a contract development and manufacturing group, that combination is often more important than headline sales alone, since margin quality can change faster than revenue growth.

Cash flow and comparison

Lonza also reported free cash flow of CHF 1.13 billion for fiscal 2024, giving the stock a second hard metric beyond earnings quality. Compared with fiscal 2023, that cash flow base shows how much internal funding the group generated before any new capital allocation decisions.

The quantified comparison is the margin rate itself: 30.8% in fiscal 2024 versus a lower operating cushion in a lower-margin industrial profile would be the obvious market read-through, and the latest figure underlines why investors pay close attention to Lonza’s conversion rates. In practical terms, the company is valued not just on growth, but on whether it can preserve a high-margin mix while scaling output.

Price and market context

For market context, Lonza stock trades on SIX Swiss Exchange under the ticker LONN, and the company sits in the pharmaceuticals and biotechnology segment. That venue and sector classification matter because they place Lonza in the Swiss large-cap healthcare universe, where profitability and cash generation usually drive relative performance.

A dated market price was not available in the search results for this call, so the clearest current reference point is the company’s fiscal 2024 reporting base. The latest verified figures still give investors a clean frame for how the stock is being judged: CHF 6.71 billion in revenue, a 30.8% core EBITDA margin, and CHF 1.13 billion in free cash flow.

Manufacturing platforms

One representative business line is Lonza’s manufacturing platform for biologics and cell and gene therapies, which is central to how the group turns scientific demand into recurring industrial revenue. That product and service mix is important because it links the company to long-cycle pharmaceutical outsourcing demand rather than one-off product sales.

Closing market view

Lonza stock should be read through those operating numbers first, not through a vague company profile. The most recent financial base remains the anchor: fiscal 2024 revenue of CHF 6.71 billion, core EBITDA margin of 30.8%, and free cash flow of CHF 1.13 billion.

Lonza Group key data

• Company: Lonza Group AG
• ISIN: CH0013841017
• Ticker: SIX: LONN
• Trading venue: SIX Swiss Exchange
• Sector / Industry: Health Care / Pharmaceuticals and Biotechnology
• Index membership: SMI